Data from: Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

Frederik Barkhof, Ludwig Kappos, Jerry S. Wolinsky, David K. B. Li, Amit Bar-Or, Hans-Peter Hartung, Shibeshih Belachew, Jian Han, Laura Julian, Annette Sauter, Julie Napieralski, Harold Koendgen & Stephen L. Hauser
Objective: To assess the onset of ocrelizumab efficacy on brain magnetic resonance imaging (MRI) measures of disease activity in the Phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse rate in the pooled Phase III studies in relapsing multiple sclerosis (RMS). Methods: Brain MRI activity was determined in the Phase II trial at monthly intervals in patients with RRMS receiving placebo, ocrelizumab (600 mg), or intramuscular interferon (IFN) β-1a (30 μg). Annualized relapse rate...
1 citation reported since publication in 2019.
198 views reported since publication in 2019.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
53 downloads reported since publication in 2019.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?